Please login to the form below

Not currently logged in
Email:
Password:

lupus

This page shows the latest lupus news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

It is however growing at a much faster rate; respiratory grew 3%, HIV was up 11% and immuno-inflammation – led by lupus drug Benlysta (belimumab) – rose 28%.

Latest news

More from news
Approximately 8 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus. ... 230. SuppreMol / Baxter. Company acquisition. Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid arthritis) stated: “Getting a correct diagnosis was

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    886. Ablynx  / AbbVie. 1. Licence. ALX0061 - anti-IL-6R nanobody for rheumatoid arthritis and lupus.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics